跳至主要内容
临床试验/KCT0007311
KCT0007311招募中未知

Changes in anti-SARS-CoV-2 antibody levels in response to COVID-19 vaccine in patients with inflammatory bowel disease

Keimyung University Dongsan Hospital0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
20(Year) 至 80(Year)(—)
性别
All

入选标准

  • 1. Patients who will receive or have received a SARS-CoV-2 booster vaccine among IBD patients aged 20 to 80 years
  • 2. Crohn's disease or ulcerative colitis patients who taking at least one of agents among 5-aminosalycylic acid (ASA), immunomodulatory agents, and biological agents (infliximab, vedolizumab, ustekinumab etc)
  • 3. A person who has signed a written consent form after agreeing to the purpose and method of the clinical research

排除标准

  • 1. Those who have passed the booster vaccination more than 12 months ago
  • 2. Those who have been diagnosed with IBD and have used IBD medications for less 3 months
  • 3. Those who have had surgery within 3 months at the time of registration
  • 4. Those who do not agree to participate in the research

研究者

发起方
Keimyung University Dongsan Hospital

相似试验